GlobeNewswire

Call for Speakers Now Open for Percona Live Open Source Database Conference Europe 2018

Dela

Annual Conference Moves to Frankfurt; Accepting Speaker Proposals Through August 10, 2018

RALEIGH, N.C., July 10, 2018 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MariaDB and MongoDB®, PostgreSQL and other open source database solutions and services, today announced the Call for Speakers for Percona Live Open Source Database Conference Europe 2018 is open and accepting proposals through August 10, 2018. The Percona Live Open Source Database Conference Europe 2018 will take place November 5-7, 2018, at the Radisson Blu Frankfurt hotel in Frankfurt, Germany. Sponsorship opportunities are now available.

The Percona Live Open Source Database Conference Europe 2018 is the premier open source database event. The theme for the upcoming conference is "Connect. Accelerate. Innovate." Percona Live conferences provide the open source database community with an opportunity to discover and discuss the latest open source trends, technologies and innovations. The conference includes the best and brightest innovators and influencers in the open source database industry.

The 2018 conference will introduce a new "business" track, which will take place on Monday, November 5. The new track will be targeted to business leaders who are exploring the use of open source and are interested in learning more about its benefits as well as common business pains and how these have been addressed through use cases and case studies.

The conference committee is looking for proposals that cover the many aspects of using, deploying and managing open source databases, including:

  • Security - All of us have experienced security challenges. Whether they are initiated by legislature (GDPR), bugs (Meltdown/Spectre), experience (external attacks) or due diligence (planning for the worst), when do you have 'enough' security? Are you finding that security requirements are preventing your from being agile?
  • Serverless, Cloud or On Premise - The technology landscape is no longer a simple one and mixing infrastructures has almost become the norm. Are you designing data architectures for the new landscape, and eager to share your experience? Have microservices become an important part of your plans?
  • MySQL - Do you have an opinion on what is new and exciting in MySQL? With the release of MySQL 8.0, are you using the latest features? How and why? Are they helping you solve any business issues, or making deployment of applications and websites easier, faster or more efficient? Did the new release get you to change to MySQL? What do you see as the biggest impact of the MySQL 8.0 release? Do you use MySQL in conjunction with other databases in your environment?
  • MongoDB - How has the 3.6 release improved your experience in application development or time-to-market? How are the new features making your database environment better? What is it about MongoDB 4.0 that excites you? What are your experiences with Atlas? Have you moved to it, and has it lived up to its promises? Do you use MongoDB in conjunction with other databases in your environment?
  • PostgreSQL - Why do you use PostgreSQL as opposed to other SQL options? Have you done a comparison or benchmark of PostgreSQL vs. other types of databases related to your tasks? Why and what were the results? How does PostgreSQL help you with application performance or deployment? How do you use PostgreSQL in conjunction with other databases in your environment?
  • SQL, NewSQL, NoSQL - It's become a perennial question without an easy answer. How do databases compare, how do you choose the right technology for the job, how do you trade off between features and their benefits in comparing databases? If you have ever tried a hybrid database approach in a single application, how did that work out? How nicely does MongoDB play with MySQL in the real world? Do you have anything to say about using SQL with NoSQL databases?
  • High Availability - What choices are you making to ensure high availability? How do you find the balance between redundancy and cost? Are you using hot backups, and if so, what happened when you needed to rollback on them? 
  • Scalability - When did you recognize you needed to address data scale? Did your data growth take you by surprise or were you always in control? Did it take a degradation in performance to get your management to sit up and take notice? How do you plan for scale if you can't predict demand?
  • What the Future Holds - What do you see as the "next big thing"? What new and exciting features are going to be released? What's in your next release? What new technologies will affect the database landscape? AI? Machine learning? Blockchain databases? Let us know about innovations you see on the way.

Breakout sessions are 50 minutes in length, including a Q&A. Tutorial sessions are three or six hours in length, focused on an immediate and practical application of in-depth knowledge, and targeted at a level between a training class and a conference breakout session. Tutorial speakers should assume that attendees will have laptops to work through detailed and potentially hands-on presentations. Lightning Talks are five-minute presentations focusing on one key point that interests the open source community: technical, lighthearted or entertaining talks on new ideas, a successful project, a cautionary story, a quick tip or demonstration.

Selected speakers will receive a complimentary full conference pass.

Sponsorships
Sponsorship opportunities for Percona Live Open Source Database Conference Europe 2018 are available and offer the opportunity to interact with hundreds of DBAs, sysadmins, developers, CTOs, CEOs, business managers, technology evangelists, solution vendors, and entrepreneurs who typically attend the event. Contact live@percona.com for sponsorship details.

Percona Live Conferences

What:               Percona Live Open Source Database Conference Europe 2018 
Where:            Radisson Blu Frankfurt, Franklinstraße 65, Frankfurt, Germany
When:              November 5-7, 2018
Call for Papers Deadline:  August 10, 2018

Company Information

Press Contact
Brigit Valencia
For Percona
(360) 597-4516
bdbvalencia@gmail.com

About Percona

With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for both MySQL® MariaDB®, MongoDB® and PostgreSQL across traditional and cloud-based platforms. The company provides SoftwareSupport,  Consulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum